Try the modernized beta website. Learn more about the modernization effort.
Working… Menu
Trial record 1 of 11 for:    Sheba | Chronic Myeloid Leukemia | Israel
Previous Study | Return to List | Next Study

Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02115672
Recruitment Status : Withdrawn (loss of support)
First Posted : April 16, 2014
Last Update Posted : August 15, 2016
Information provided by (Responsible Party):
Sheba Medical Center

Brief Summary:
The aim of the study is to test the safety and efficacy of BL-8040 (a CXCR4 antagonist) in improving the response to imatinib in CML patients not achieving an optimal response with imatinib alone.

Condition or disease Intervention/treatment Phase
Chronic Myeloid Leukemia Drug: BL-8040 Phase 1 Phase 2

Detailed Description:
To improve cytogenetic and molecular response of CML patients receiving Imatinib, who have not achieved an optimal response according to European LeukemiaNet (ELN) definitions , or MR4 after 24 months with Imatinib. This will be achieved by addition of the CXCR4 antagonist BL-8040, mobilizing CML leukemia stem cells from their protective bone marrow niche and exposing them to Imatinib and BL-8040-mediated apoptosis.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I/II Study Using Imatinib and s.c. BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia (CML) Patients in First Chronic Phase Achieving Less Than Optimal Response With Imatinib.
Study Start Date : November 2014
Estimated Primary Completion Date : November 2016
Estimated Study Completion Date : November 2018

Arm Intervention/treatment
Experimental: BL-8040
Patients with chronic phase CML on Imatinib therapy (400 mg/day) achieving less than an optimal response will be treated with sc injections of BL-8040, while continuing Imatinib. The first part of the study will include escalating dose groups. Up to 4 dose levels will be investigated starting at dose level 1. Patients will be accrued in a conventional 3+3 design. Applying this study design, the first cohort of 3 patients will be treated at dose level 1 (0.5 mg/kg) on Day 1, 15, 29 and 43. Patients will continue taking Imatinib 400 mg/day throughout the study. Dose escalation will continue until the maximal tolerated dose (MTD) is established and protocol specific stopping rules for toxicity are met. If no MTD is reached, dose escalation will continue up to dose level 4 (1.25 mg/kg).
Drug: BL-8040
BL-8040 will be added to imatinib to improve CML response.

Primary Outcome Measures :
  1. To assess the safety and tolerability of BL-8040 in combination with Imatinib in CML patients [ Time Frame: 4 months ]
    The investigators will assess the safety of the BL-8040 by grading of toxicities according to standard Common Toxicity Criteria for Adverse Effects (CTCAE) criteria.

Secondary Outcome Measures :
  1. To assess the clinical efficacy of BL-8040 in combination with Imatinib [ Time Frame: 2 years ]
    The cytogenetic and molecular response will be assessed by standard FISH and PCR test according to established criteria.

Other Outcome Measures:
  1. To assess additional pharmacodynamic parameters relevant to CXCR4 inhibition [ Time Frame: 2 months ]
    The investigators will test CXCR4 receptor occupancy and expression and additional pharmacodynamic endpoints relevant to CXCR4 inhibition.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Adult men and women subjects aged 18 to 70, inclusive.
  2. Confirmed diagnosis of chronic phase CML according to the WHO criteria (WHO 2008)
  3. CML patients with sub-optimal response to Tyrosine Kinase Inhibitors, defined as "warning" in the ELN recommendations:

    Following 3 months: BCR-ABL1 > 10%, and/or Ph+ 36-95% Following 6 months: BCR-ABL1 1-10%, and/or Ph + 1-35% Following 12 months: BCR-ABL1 0.1-1 % Following 24 months: Less than MR4

  4. Clinical laboratory values should be as follows:

    White blood cell count < 30 X 10*9/L Creatinine < 1.5 ULN

  5. Women of childbearing potential and all men must agree to use approved form of contraception
  6. Subject is able and willing to comply with the requirements of the protocol.
  7. Subject is able to voluntarily provide written informed consent.

Exclusion Criteria:

  1. CML patients not in chronic phase.
  2. CML patients receiving Tyrosine Kinase Inhibitors other than Imatinib.
  3. CML patients receiving Imatinib > 400 mg/day.
  4. Patients not able to sign informed consent.
  5. Known allergy or hypersensitivity to any of the test compounds or materials or contraindication to test product.
  6. Low Performance Status (ECOG > 2).
  7. Abnormal liver function tests:

    1. Serum aspartate transaminase (AST/SGOT) or alanine transaminase (ALT/SGPT) 2 x upper limit of normal (ULN).
    2. Serum bilirubin. Total bilirubin > 2.0 mg/dL (34 µmol/L), conjugated bilirubin > 0.8 mg/dL
  8. Abnormal left ventricular ejection fraction, < 40 %.
  9. Subject has concurrent, uncontrolled medical condition, laboratory abnormality, or psychiatric illness which could place him/her at unacceptable risk, including, but not limited to:

    1. Subject has been diagnosed or treated for another malignancy within 3 years of enrolment, except in situ malignancy, or low-risk prostate, skin or cervix cancer after curative therapy
    2. A co-morbid condition which, in the view of the Investigators, renders the subject at high risk from treatment complications.
  10. Women subjects who are pregnant or breastfeeding.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02115672

Layout table for location information
Chaim Sheba Medical Center
Tel-Hashomer, Israel, 52621
Sponsors and Collaborators
Sheba Medical Center
Layout table for investigator information
Principal Investigator: Arnon Nagler, MD Chaim Sheba Medical Center
Layout table for additonal information
Responsible Party: Sheba Medical Center Identifier: NCT02115672    
Other Study ID Numbers: SHEBA-13-0575-AN-CTIL
First Posted: April 16, 2014    Key Record Dates
Last Update Posted: August 15, 2016
Last Verified: December 2014
Keywords provided by Sheba Medical Center:
Chronic myeloid leukemia
CXCR4 antagonist
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Myeloid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Neoplasms by Histologic Type
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases